Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Breast Neoplasms 577Carcinoma, Non-Small-Cell Lung 491Ovarian Neoplasms 328Lung Neoplasms 208Fallopian Tube Neoplasms 153Neoplasms 152Stomach Neoplasms 128Esophageal Neoplasms 127Triple Negative Breast Neoplasms 125Neoplasm Metastasis 121Carcinoma, Ovarian Epithelial 115Squamous Cell Carcinoma of Head and Neck 96Endometrial Neoplasms 95Uterine Cervical Neoplasms 80Head and Neck Neoplasms 78Esophageal Squamous Cell Carcinoma 77Adenocarcinoma of Lung 49Recurrence 48Parkinson Disease 4, Autosomal Dominant Lewy Body 45Melanoma 42Carcinoma 42Urinary Bladder Neoplasms 41Adenocarcinoma Of Esophagus 36Small Cell Lung Carcinoma 34Carcinoma, Squamous Cell 34Prostatic Neoplasms 32Pancreatic Neoplasms 30Breast Neoplasms, Male 28Unspecified Adult Solid Tumor, Protocol Specific 27Adenocarcinoma, Bronchiolo-Alveolar 26

Interventions

Chemoradiotherapy 2Radiation 1Paclitaxel 1Granulocyte-Macrophage Colony-Stimulating Factor 1Colony-Stimulating Factors 1Cetuximab 1Carboplatin 1Adjuvants, Immunologic 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Resectable Esophageal Cancer × Paclitaxel × Clear all
NCT03490292 2024-07-26

Avelumab With Chemoradiation for Stage II/III Resectable Esophageal and Gastroesophageal Cancer

University of Wisconsin, Madison

Phase 1/2 Completed
22 enrolled 17 charts
Gastrointestinal

Resectable Esophageal Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡